Suppr超能文献

减少同时存在酒精问题和非法药物使用问题者饮酒量的心理社会干预措施。

Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users.

作者信息

Klimas Jan, Tobin Helen, Field Catherine-Anne, O'Gorman Clodagh S M, Glynn Liam G, Keenan Eamon, Saunders Jean, Bury Gerard, Dunne Colum, Cullen Walter

机构信息

Addiction & Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, 611 Powell Street, Vancouver, BC, V6A 1H2, Canada.

出版信息

Cochrane Database Syst Rev. 2014 Dec 3(12):CD009269. doi: 10.1002/14651858.CD009269.pub3.

Abstract

BACKGROUND

Problem alcohol use is common among illicit drug users and is associated with adverse health outcomes. It is also an important factor contributing to a poor prognosis among drug users with hepatitis C virus (HCV) as it impacts on progression to hepatic cirrhosis or opiate overdose in opioid users.

OBJECTIVES

To assess the effects of psychosocial interventions for problem alcohol use in illicit drug users (principally problem drug users of opiates and stimulants).

SEARCH METHODS

We searched the Cochrane Drugs and Alcohol Group trials register (June 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 11, June 2014), MEDLINE (1966 to June 2014); EMBASE (1974 to June 2014); CINAHL (1982 to June 2014); PsycINFO (1872 to June 2014) and the reference lists of eligible articles. We also searched: 1) conference proceedings (online archives only) of the Society for the Study of Addiction, International Harm Reduction Association, International Conference on Alcohol Harm Reduction and American Association for the Treatment of Opioid Dependence; 2) online registers of clinical trials: Current Controlled Trials, Clinical Trials.org, Center Watch and the World Health Organization International Clinical Trials Registry Platform.

SELECTION CRITERIA

Randomised controlled trials comparing psychosocial interventions with another therapy (other psychosocial treatment, including non-pharmacological therapies, or placebo) in adult (over the age of 18 years) illicit drug users with concurrent problem alcohol use.

DATA COLLECTION AND ANALYSIS

We used the standard methodological procedures expected by The Cochrane Collaboration.

MAIN RESULTS

Four studies, involving 594 participants, were included. Half of the trials were rated as having a high or unclear risk of bias. The studies considered six different psychosocial interventions grouped into four comparisons: (1) cognitive-behavioural coping skills training versus 12-step facilitation (one study; 41 participants), (2) brief intervention versus treatment as usual (one study; 110 participants), (3) group or individual motivational interviewing (MI) versus hepatitis health promotion (one study; 256 participants) and (4) brief motivational intervention (BMI) versus assessment-only (one study; 187 participants). Differences between studies precluded any data pooling. Findings are described for each trial individually.Comparison 1: low-quality evidence; no significant difference for any of the outcomes considered Alcohol abstinence as maximum number of weeks of consecutive alcohol abstinence during treatment: mean difference (MD) 0.40 (95% confidence interval (CI) -1.14 to 1.94); illicit drug abstinence as maximum number of weeks of consecutive abstinence from cocaine during treatment: MD 0.80 (95% CI -0.70 to 2.30); alcohol abstinence as number achieving three or more weeks of consecutive alcohol abstinence during treatment: risk ratio (RR) 1.96 (95% CI 0.43 to 8.94); illicit drug abstinence as number achieving three or more weeks of consecutive abstinence from cocaine during treatment: RR 1.10 (95% CI 0.42 to 2.88); alcohol abstinence during follow-up year: RR 2.38 (95% CI 0.10 to 55.06); illicit drug abstinence as abstinence from cocaine during follow-up year: RR 0.39 (95% CI 0.04 to 3.98), moderate-quality evidence.Comparison 2: low-quality evidence, no significant difference for all the outcomes considered Alcohol use as AUDIT scores at three months: MD 0.80 (95% -1.80 to 3.40); alcohol use as AUDIT scores at nine months: MD 2.30 (95% CI -0.58 to 5.18); alcohol use as number of drinks per week at three months: MD 0.70 (95% CI -3.85 to 5.25); alcohol use as number of drinks per week at nine months: MD -0.30 (95% CI -4.79 to 4.19); alcohol use as decreased alcohol use at three months: RR 1.13 (95% CI 0.67 to 1.93); alcohol use as decreased alcohol use at nine months: RR 1.34 (95% CI 0.69 to 2.58), moderate-quality evidence.Comparison 3 (group and individual MI), low-quality evidence: no significant difference for all outcomes Group MI: number of standard drinks consumed per day over the past month: MD -0.40 (95% CI -2.03 to 1.23); frequency of drug use: MD 0.00 (95% CI -0.03 to 0.03); composite drug score (frequencyseverity for all drugs taken): MD 0.00 (95% CI -0.42 to 0.42); greater than 50% reduction in number of standard drinks consumed per day over the last 30 days: RR 1.10 (95% CI 0.82 to 1.48); abstinence from alcohol over the last 30 days: RR 0.88 (95% CI 0.49 to 1.58).Individual MI: number of standard drinks consumed per day over the past month: MD -0.10 (95% CI -1.89 to 1.69); frequency of drug use (as measured using the Addiction Severity Index (ASI drug): MD 0.00 (95% CI -0.03 to 0.03); composite drug score (frequencyseverity for all drugs taken): MD -0.10 (95% CI -0.46 to 0.26); greater than 50% reduction in number of standard drinks consumed per day over the last 30 days: RR 0.92 (95% CI 0.68 to 1.26); abstinence from alcohol over the last 30 days: RR 0.97 (95% CI 0.56 to 1.67).Comparison 4: more people reduced alcohol use (by seven or more days in the past month at 6 months) in the BMI group than in the control group (RR 1.67; 95% CI 1.08 to 2.60), moderate-quality evidence. No significant difference was reported for all other outcomes: number of days in the past 30 days with alcohol use at one month: MD -0.30 (95% CI -3.38 to 2.78); number of days in the past month with alcohol use at six months: MD -1.50 (95% CI -4.56 to 1.56); 25% reduction of drinking days in the past month: RR 1.23 (95% CI 0.96 to 1.57); 50% reduction of drinking days in the past month: RR 1.27 (95% CI 0.96 to 1.68); 75% reduction of drinking days in the past month: RR 1.21 (95% CI 0.84 to 1.75); one or more drinking days' reduction in the past month: RR 1.12 (95% CI 0.91 to 1.38).

AUTHORS' CONCLUSIONS: There is low-quality evidence to suggest that there is no difference in effectiveness between different types of interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users and that brief interventions are not superior to assessment-only or to treatment as usual. No firm conclusions can be made because of the paucity of the data and the low quality of the retrieved studies.

摘要

背景

问题性饮酒在非法药物使用者中很常见,且与不良健康后果相关。它也是导致丙型肝炎病毒(HCV)感染的药物使用者预后不良的一个重要因素,因为它会影响到进展为肝硬化或导致阿片类药物使用者阿片过量。

目的

评估针对非法药物使用者(主要是阿片类和兴奋剂类问题药物使用者)的问题性饮酒的心理社会干预措施的效果。

检索方法

我们检索了Cochrane药物与酒精研究组试验注册库(2014年6月)、Cochrane对照试验中心注册库(CENTRAL)(Cochrane图书馆,2014年第11期)、MEDLINE(1966年至2014年6月);EMBASE(1974年至2014年6月);CINAHL(1982年至2014年6月);PsycINFO(1872年至2014年6月)以及符合条件文章的参考文献列表。我们还检索了:1)成瘾研究学会、国际减少伤害协会、酒精危害减少国际会议和美国阿片类药物依赖治疗协会的会议论文集(仅在线存档);2)临床试验在线注册库:当前对照试验、ClinicalTrials.org、Center Watch和世界卫生组织国际临床试验注册平台。

选择标准

随机对照试验,比较心理社会干预措施与另一种疗法(其他心理社会治疗,包括非药物疗法或安慰剂)在成年(18岁以上)同时存在问题性饮酒的非法药物使用者中的效果。

数据收集与分析

我们采用了Cochrane协作网期望的标准方法程序。

主要结果

纳入了4项研究,涉及594名参与者。一半的试验被评为具有高或不明确的偏倚风险。这些研究考虑了六种不同的心理社会干预措施,分为四个比较组:(1)认知行为应对技能训练与12步促进法(一项研究;41名参与者),(2)简短干预与常规治疗(一项研究;110名参与者),(3)团体或个体动机性访谈(MI)与肝炎健康促进(一项研究;256名参与者)以及(4)简短动机性干预(BMI)与仅评估(一项研究;187名参与者)。研究之间的差异使得无法进行任何数据合并。对每项试验分别描述结果。比较1:低质量证据;所考虑的任何结局均无显著差异。戒酒定义为治疗期间连续戒酒的最长周数:平均差(MD)0.40(95%置信区间(CI)-1.14至1.94);非法药物戒断定义为治疗期间连续戒除可卡因的最长周数:MD 0.80(95%CI -0.70至2.30);戒酒定义为治疗期间实现连续三周或更长时间戒酒的人数:风险比(RR)1.96(95%CI 0.43至8.94);非法药物戒断定义为治疗期间实现连续三周或更长时间戒除可卡因的人数:RR 1.10(95%CI 0.42至2.88);随访年度的戒酒情况:RR 2.38(95%CI 0.10至55.06);随访年度的非法药物戒断情况(定义为戒除可卡因):RR 0.39(X 95%CI 0.04至3.98),中等质量证据。比较2:低质量证据,所考虑的所有结局均无显著差异。饮酒情况用三个月时的AUDIT评分衡量:MD 0.80(95% -1.80至3.40);饮酒情况用九个月时的AUDIT评分衡量:MD 2.30(95%CI -0.58至5.18);饮酒情况用三个月时每周饮酒量衡量:MD 0.70(95%CI -3.85至5.25);饮酒情况用九个月时每周饮酒量衡量:MD -0.30(95%CI -4.79至4.19);饮酒情况用三个月时饮酒量减少衡量:RR 1.13(95%CI 0.67至1.93);饮酒情况用九个月时饮酒量减少衡量:RR 1.34(95%CI 0.69至2.58),中等质量证据。比较3(团体和个体MI),低质量证据:所有结局均无显著差异。团体MI:过去一个月每天饮用的标准饮料数量:MD -0.40(95%CI -2.03至1.23);药物使用频率:MD (95%CI -0.0到0.03);复合药物评分(所有服用药物的频率严重程度):MD 0.00(95%CI -0.42至0.42);过去30天内每天饮用的标准饮料数量减少超过(95%CI 0.82至1.48);过去30天内戒酒:RR 0.88(95%CI 0.49至1.58)。个体MI:过去一个月每天饮用的标准饮料数量:MD -0.10(95%CI -1.89至1.69);药物使用频率(使用成瘾严重程度指数(ASI药物)测量):MD 0.00(95%CI -0.03至0.03);复合药物评分(所有服用药物的频率严重程度):MD -0.10(95%CI -0.46至0.26);过去30天内每天饮用的标准饮料数量减少超过50%:RR 0.92(95%CI 0.68至1.26);过去30天内戒酒:RR 0.97(95%CI 0.56至1.67)。比较4:BMI组中在过去一个月减少饮酒天数(6个月时减少7天或更多)的人数比对照组多(RR 1.67;95%CI 1.08至2.60),中等质量证据。所有其他结局均未报告显著差异:一个月时过去30天内饮酒的天数:MD -0.30(95%CI -3.38至2.78);六个月时过去一个月内饮酒的天数:MD -1.50(95%CI -4.56至1.56);过去一个月内饮酒天数减少25%:RR 1.23(95%CI 0.96至1.57);过去一个月内饮酒天数减少50%:RR 1.27(95%CI 0.96至1.68);过去一个月内饮酒天数减少75%:RR 1.21(95%CI 0.84至1.75);过去一个月内饮酒天数减少一天或更多:RR 1.12(95%CI 0.91至1.38)。

作者结论

低质量证据表明,在同时存在问题性饮酒和非法药物使用的人群中,不同类型的减少酒精消费干预措施在有效性上没有差异,并且简短干预并不优于仅评估或常规治疗。由于数据匮乏以及所检索研究质量较低,无法得出确切结论。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验